Literature DB >> 16514305

Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.

Colette Smit1, Ronald Geskus, Sarah Walker, Caroline Sabin, Roel Coutinho, Kholoud Porter, Maria Prins.   

Abstract

INTRODUCTION: Although HAART has led to a reduction in overall mortality among HIV-infected individuals, its impact on death from specific causes is unknown.
METHODS: Twenty-two cohorts of HIV-infected individuals with known dates of seroconversion are pooled in the CASCADE collaboration. Causes of death (COD) were categorized into three AIDS-related and seven non-AIDS-related causes. The unknown causes were assigned a separate category. The cumulative incidence for each COD was calculated in the presence of the other competing COD, for the pre-HAART and HAART eras. A multivariate regression analyses for the cumulative rate of progression to the different COD was performed.
RESULTS: A total of 1938 of 7680 HIV-seroconverters died. Pre-HAART, AIDS opportunistic infections (OI) was the most common COD, followed by unknown and HIV/AIDS-unspecified. In the HAART era, the cumulative incidence for all AIDS-related COD decreased, OI remaining the most important. Large reductions in death due to other infections and organ failure were seen. Cumulative death risk decreased in the HAART era for most causes. The effect of HAART was not the same for all risk groups. The cumulative risk of death from AIDS-related malignancies, OI and non-AIDS-related malignancies decreased significantly among homosexual men (MSM), whereas the risk of dying from (un)-intentional death increased significantly among injecting drug users (IDU). A non-significant increase in hepatitis/liver-related death was seen in MSM, IDU and haemophiliacs.
CONCLUSION: Overall and cause specific mortality decreased following the introduction of HAART. OI remain the most common COD in the HAART era, suggesting that AIDS-related events will continue to be important in the future. Future trends in COD should be monitored using standardized guidelines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16514305     DOI: 10.1097/01.aids.0000216375.99560.a2

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  77 in total

1.  Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients.

Authors:  H Lim; L Kane; J B Schwartz; C S Hesdorffer; S G Deeks; N Greig; L Ferrucci; E J Goetzl
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

2.  Improving survival among HIV-infected injection drug users: how should we define success?

Authors:  Gregory D Kirk; David Vlahov
Journal:  Clin Infect Dis       Date:  2007-06-19       Impact factor: 9.079

3.  AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment.

Authors:  Kathleen Falster; Jun Yong Choi; Basil Donovan; Chris Duncombe; Brian Mulhall; David Sowden; Jialun Zhou; Matthew G Law
Journal:  AIDS       Date:  2009-11-13       Impact factor: 4.177

4.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

5.  Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use.

Authors:  Nicolas Magné; Cyrus Chargari; Antonin Levy; Jean-Baptiste Guy; Yacine Merrouche; Jean-Philippe Spano
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

6.  Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden.

Authors:  Stephen R Cole; Sonia Napravnik; Michael J Mugavero; Bryan Lau; Joseph J Eron; Michael S Saag
Journal:  Am J Epidemiol       Date:  2009-12-09       Impact factor: 4.897

7.  Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study.

Authors:  Basmattee Boodram; Michael W Plankey; Christopher Cox; Phyllis C Tien; Mardge H Cohen; Kathryn Anastos; Roksana Karim; Charles Hyman; Ronald C Hershow
Journal:  AIDS Patient Care STDS       Date:  2009-12       Impact factor: 5.078

8.  High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection.

Authors:  Jason Baker; Woubeshet Ayenew; Harrison Quick; Katherine Huppler Hullsiek; Russell Tracy; Keith Henry; Daniel Duprez; James D Neaton
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

9.  Elevated risks of death for diabetes mellitus and cardiovascular diseases in Italian AIDS cases.

Authors:  Diego Serraino; Silvia Bruzzone; Antonella Zucchetto; Barbara Suligoi; Angela De Paoli; Simona Pennazza; Laura Camoni; Luigino Dal Maso; Paoli De Paoli; Giovanni Rezza
Journal:  AIDS Res Ther       Date:  2010-05-24       Impact factor: 2.250

10.  Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study.

Authors:  Vincent C Marconi; Greg A Grandits; Amy C Weintrob; Helen Chun; Michael L Landrum; Anuradha Ganesan; Jason F Okulicz; Nancy Crum-Cianflone; Robert J O'Connell; Alan Lifson; Glenn W Wortmann; Brian K Agan
Journal:  AIDS Res Ther       Date:  2010-05-27       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.